Targeting the Wnt/beta-catenin pathway in renal cell carcinoma

Advanced renal cancer still has a very poor prognosis. In this regard recent investigations demonstrated a constitutive activation of the Wnt signaling pathway in renal cell carcinoma (RCC) thereby promoting an exaggerated cell proliferation. Especially, β-catenin overactivation and the functional l...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Anticancer research 2014-08, Vol.34 (8), p.4101
Hauptverfasser: Von Schulz-Hausmann, Sarah Annette, Schmeel, Leonard Christopher, Schmeel, Frederic Carsten, Schmidt-Wolf, Ingo G H
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 8
container_start_page 4101
container_title Anticancer research
container_volume 34
creator Von Schulz-Hausmann, Sarah Annette
Schmeel, Leonard Christopher
Schmeel, Frederic Carsten
Schmidt-Wolf, Ingo G H
description Advanced renal cancer still has a very poor prognosis. In this regard recent investigations demonstrated a constitutive activation of the Wnt signaling pathway in renal cell carcinoma (RCC) thereby promoting an exaggerated cell proliferation. Especially, β-catenin overactivation and the functional loss of endogenous Wnt antagonists are associated with RCC carcinogenesis and progression. Thus, influencing Wnt signaling might represent a promising target in RCC treatment. It was recently confirmed that ethacrynic acid (EA), ciclopirox olamine (CIC) and piroctone olamine (PO) can inhibit Wnt signaling in various cancer cell lines. Herein we investigated their cytotoxic potential towards human RCC cells and their influence on the Wnt pathway concerning apoptosis as determined by 3,3'-dihexyloxacarbocyanine iodide (DiOC6) and propidium iodide (PI) staining in flow cytometry and immunoblotting. All three agents, EA, CIC and PO triggered a significant apoptotic activity in tested RCC cell lines in a time- and concentration-dependent manner. Moreover, exposure to CIC and PO decreased the expression of β-catenin as the pivotal feature within the canonical Wnt pathway. However, β-catenin expression increased upon the treatment with EA. These results reveal a significant selective induction of apoptosis by EA, CIC and PO and suggest a suppression of RCC survival in part due to inhibition of Wnt/β-catenin signaling. The development of targeted-therapies affecting the Wnt signaling pathway might therefore lead to novel treatment options for RCC patients.
format Article
fullrecord <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_25075035</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>25075035</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-b53677ffa4a47c7b1fd57d0fa9e9777678b2faba35c0b0ca6f54952d80fe54da3</originalsourceid><addsrcrecordid>eNo1j81KAzEURoMgtlZfQfICwWQyN3eyEaT4BwU3FZfl5q8dmYlDJiJ9ewvq5jtndeA7Y0uFVgkELRfscp4_pDTGdvqCLRqQCFLDkt1tqexj7fOe10Pk77neulhJeKox95lPVA_fdOQnLTHTwH0cTkPF9_lzpCt2nmiY4_UfV-zt8WG7fhab16eX9f1GTI1SVTjQBjElaqlFj06lABhkIhstIhrsXJPIkQYvnfRkErQWmtDJFKENpFfs5rc7fbkxht1U-pHKcfd_RP8A0PpD-g</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Targeting the Wnt/beta-catenin pathway in renal cell carcinoma</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Von Schulz-Hausmann, Sarah Annette ; Schmeel, Leonard Christopher ; Schmeel, Frederic Carsten ; Schmidt-Wolf, Ingo G H</creator><creatorcontrib>Von Schulz-Hausmann, Sarah Annette ; Schmeel, Leonard Christopher ; Schmeel, Frederic Carsten ; Schmidt-Wolf, Ingo G H</creatorcontrib><description>Advanced renal cancer still has a very poor prognosis. In this regard recent investigations demonstrated a constitutive activation of the Wnt signaling pathway in renal cell carcinoma (RCC) thereby promoting an exaggerated cell proliferation. Especially, β-catenin overactivation and the functional loss of endogenous Wnt antagonists are associated with RCC carcinogenesis and progression. Thus, influencing Wnt signaling might represent a promising target in RCC treatment. It was recently confirmed that ethacrynic acid (EA), ciclopirox olamine (CIC) and piroctone olamine (PO) can inhibit Wnt signaling in various cancer cell lines. Herein we investigated their cytotoxic potential towards human RCC cells and their influence on the Wnt pathway concerning apoptosis as determined by 3,3'-dihexyloxacarbocyanine iodide (DiOC6) and propidium iodide (PI) staining in flow cytometry and immunoblotting. All three agents, EA, CIC and PO triggered a significant apoptotic activity in tested RCC cell lines in a time- and concentration-dependent manner. Moreover, exposure to CIC and PO decreased the expression of β-catenin as the pivotal feature within the canonical Wnt pathway. However, β-catenin expression increased upon the treatment with EA. These results reveal a significant selective induction of apoptosis by EA, CIC and PO and suggest a suppression of RCC survival in part due to inhibition of Wnt/β-catenin signaling. The development of targeted-therapies affecting the Wnt signaling pathway might therefore lead to novel treatment options for RCC patients.</description><identifier>EISSN: 1791-7530</identifier><identifier>PMID: 25075035</identifier><language>eng</language><publisher>Greece</publisher><subject>beta Catenin - antagonists &amp; inhibitors ; beta Catenin - physiology ; Carcinoma, Renal Cell - drug therapy ; Carcinoma, Renal Cell - pathology ; Cell Line, Tumor ; Cell Survival - drug effects ; Ciclopirox ; Drug Combinations ; Ethacrynic Acid - pharmacology ; Ethanolamines - pharmacology ; Humans ; Kidney Neoplasms - drug therapy ; Kidney Neoplasms - pathology ; Pyridones - pharmacology ; Wnt Signaling Pathway - drug effects ; Wnt Signaling Pathway - physiology</subject><ispartof>Anticancer research, 2014-08, Vol.34 (8), p.4101</ispartof><rights>Copyright© 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25075035$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Von Schulz-Hausmann, Sarah Annette</creatorcontrib><creatorcontrib>Schmeel, Leonard Christopher</creatorcontrib><creatorcontrib>Schmeel, Frederic Carsten</creatorcontrib><creatorcontrib>Schmidt-Wolf, Ingo G H</creatorcontrib><title>Targeting the Wnt/beta-catenin pathway in renal cell carcinoma</title><title>Anticancer research</title><addtitle>Anticancer Res</addtitle><description>Advanced renal cancer still has a very poor prognosis. In this regard recent investigations demonstrated a constitutive activation of the Wnt signaling pathway in renal cell carcinoma (RCC) thereby promoting an exaggerated cell proliferation. Especially, β-catenin overactivation and the functional loss of endogenous Wnt antagonists are associated with RCC carcinogenesis and progression. Thus, influencing Wnt signaling might represent a promising target in RCC treatment. It was recently confirmed that ethacrynic acid (EA), ciclopirox olamine (CIC) and piroctone olamine (PO) can inhibit Wnt signaling in various cancer cell lines. Herein we investigated their cytotoxic potential towards human RCC cells and their influence on the Wnt pathway concerning apoptosis as determined by 3,3'-dihexyloxacarbocyanine iodide (DiOC6) and propidium iodide (PI) staining in flow cytometry and immunoblotting. All three agents, EA, CIC and PO triggered a significant apoptotic activity in tested RCC cell lines in a time- and concentration-dependent manner. Moreover, exposure to CIC and PO decreased the expression of β-catenin as the pivotal feature within the canonical Wnt pathway. However, β-catenin expression increased upon the treatment with EA. These results reveal a significant selective induction of apoptosis by EA, CIC and PO and suggest a suppression of RCC survival in part due to inhibition of Wnt/β-catenin signaling. The development of targeted-therapies affecting the Wnt signaling pathway might therefore lead to novel treatment options for RCC patients.</description><subject>beta Catenin - antagonists &amp; inhibitors</subject><subject>beta Catenin - physiology</subject><subject>Carcinoma, Renal Cell - drug therapy</subject><subject>Carcinoma, Renal Cell - pathology</subject><subject>Cell Line, Tumor</subject><subject>Cell Survival - drug effects</subject><subject>Ciclopirox</subject><subject>Drug Combinations</subject><subject>Ethacrynic Acid - pharmacology</subject><subject>Ethanolamines - pharmacology</subject><subject>Humans</subject><subject>Kidney Neoplasms - drug therapy</subject><subject>Kidney Neoplasms - pathology</subject><subject>Pyridones - pharmacology</subject><subject>Wnt Signaling Pathway - drug effects</subject><subject>Wnt Signaling Pathway - physiology</subject><issn>1791-7530</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1j81KAzEURoMgtlZfQfICwWQyN3eyEaT4BwU3FZfl5q8dmYlDJiJ9ewvq5jtndeA7Y0uFVgkELRfscp4_pDTGdvqCLRqQCFLDkt1tqexj7fOe10Pk77neulhJeKox95lPVA_fdOQnLTHTwH0cTkPF9_lzpCt2nmiY4_UfV-zt8WG7fhab16eX9f1GTI1SVTjQBjElaqlFj06lABhkIhstIhrsXJPIkQYvnfRkErQWmtDJFKENpFfs5rc7fbkxht1U-pHKcfd_RP8A0PpD-g</recordid><startdate>201408</startdate><enddate>201408</enddate><creator>Von Schulz-Hausmann, Sarah Annette</creator><creator>Schmeel, Leonard Christopher</creator><creator>Schmeel, Frederic Carsten</creator><creator>Schmidt-Wolf, Ingo G H</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>201408</creationdate><title>Targeting the Wnt/beta-catenin pathway in renal cell carcinoma</title><author>Von Schulz-Hausmann, Sarah Annette ; Schmeel, Leonard Christopher ; Schmeel, Frederic Carsten ; Schmidt-Wolf, Ingo G H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-b53677ffa4a47c7b1fd57d0fa9e9777678b2faba35c0b0ca6f54952d80fe54da3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>beta Catenin - antagonists &amp; inhibitors</topic><topic>beta Catenin - physiology</topic><topic>Carcinoma, Renal Cell - drug therapy</topic><topic>Carcinoma, Renal Cell - pathology</topic><topic>Cell Line, Tumor</topic><topic>Cell Survival - drug effects</topic><topic>Ciclopirox</topic><topic>Drug Combinations</topic><topic>Ethacrynic Acid - pharmacology</topic><topic>Ethanolamines - pharmacology</topic><topic>Humans</topic><topic>Kidney Neoplasms - drug therapy</topic><topic>Kidney Neoplasms - pathology</topic><topic>Pyridones - pharmacology</topic><topic>Wnt Signaling Pathway - drug effects</topic><topic>Wnt Signaling Pathway - physiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Von Schulz-Hausmann, Sarah Annette</creatorcontrib><creatorcontrib>Schmeel, Leonard Christopher</creatorcontrib><creatorcontrib>Schmeel, Frederic Carsten</creatorcontrib><creatorcontrib>Schmidt-Wolf, Ingo G H</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Anticancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Von Schulz-Hausmann, Sarah Annette</au><au>Schmeel, Leonard Christopher</au><au>Schmeel, Frederic Carsten</au><au>Schmidt-Wolf, Ingo G H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Targeting the Wnt/beta-catenin pathway in renal cell carcinoma</atitle><jtitle>Anticancer research</jtitle><addtitle>Anticancer Res</addtitle><date>2014-08</date><risdate>2014</risdate><volume>34</volume><issue>8</issue><spage>4101</spage><pages>4101-</pages><eissn>1791-7530</eissn><abstract>Advanced renal cancer still has a very poor prognosis. In this regard recent investigations demonstrated a constitutive activation of the Wnt signaling pathway in renal cell carcinoma (RCC) thereby promoting an exaggerated cell proliferation. Especially, β-catenin overactivation and the functional loss of endogenous Wnt antagonists are associated with RCC carcinogenesis and progression. Thus, influencing Wnt signaling might represent a promising target in RCC treatment. It was recently confirmed that ethacrynic acid (EA), ciclopirox olamine (CIC) and piroctone olamine (PO) can inhibit Wnt signaling in various cancer cell lines. Herein we investigated their cytotoxic potential towards human RCC cells and their influence on the Wnt pathway concerning apoptosis as determined by 3,3'-dihexyloxacarbocyanine iodide (DiOC6) and propidium iodide (PI) staining in flow cytometry and immunoblotting. All three agents, EA, CIC and PO triggered a significant apoptotic activity in tested RCC cell lines in a time- and concentration-dependent manner. Moreover, exposure to CIC and PO decreased the expression of β-catenin as the pivotal feature within the canonical Wnt pathway. However, β-catenin expression increased upon the treatment with EA. These results reveal a significant selective induction of apoptosis by EA, CIC and PO and suggest a suppression of RCC survival in part due to inhibition of Wnt/β-catenin signaling. The development of targeted-therapies affecting the Wnt signaling pathway might therefore lead to novel treatment options for RCC patients.</abstract><cop>Greece</cop><pmid>25075035</pmid></addata></record>
fulltext fulltext
identifier EISSN: 1791-7530
ispartof Anticancer research, 2014-08, Vol.34 (8), p.4101
issn 1791-7530
language eng
recordid cdi_pubmed_primary_25075035
source MEDLINE; EZB-FREE-00999 freely available EZB journals
subjects beta Catenin - antagonists & inhibitors
beta Catenin - physiology
Carcinoma, Renal Cell - drug therapy
Carcinoma, Renal Cell - pathology
Cell Line, Tumor
Cell Survival - drug effects
Ciclopirox
Drug Combinations
Ethacrynic Acid - pharmacology
Ethanolamines - pharmacology
Humans
Kidney Neoplasms - drug therapy
Kidney Neoplasms - pathology
Pyridones - pharmacology
Wnt Signaling Pathway - drug effects
Wnt Signaling Pathway - physiology
title Targeting the Wnt/beta-catenin pathway in renal cell carcinoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T03%3A52%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Targeting%20the%20Wnt/beta-catenin%20pathway%20in%20renal%20cell%20carcinoma&rft.jtitle=Anticancer%20research&rft.au=Von%20Schulz-Hausmann,%20Sarah%20Annette&rft.date=2014-08&rft.volume=34&rft.issue=8&rft.spage=4101&rft.pages=4101-&rft.eissn=1791-7530&rft_id=info:doi/&rft_dat=%3Cpubmed%3E25075035%3C/pubmed%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/25075035&rfr_iscdi=true